Updated on 2025/03/14

写真a

 
UEKI Yushi
 
Organization
Academic Assembly Institute of Medicine and Dentistry IGAKU KEIRETU Associate Professor
Graduate School of Medical and Dental Sciences Biological Functions and Medical Control Sensory and Integrative Medicine Associate Professor
Title
Associate Professor
Contact information
メールアドレス
External link

Degree

  • 学士(医学) ( 2003.3   新潟大学 )

Research Interests

  • PLOD2

  • 免疫チェックポイント阻害剤治療と好酸球数変化の関連性

  • シスプラチン不耐頭頸部癌症例への治療最適化

  • がんの浸潤・転移

Research Areas

  • Life Science / Otorhinolaryngology  / 頭頸部癌

  • Life Science / Molecular biology

Research History (researchmap)

  • 新潟大学医学部   耳鼻咽喉科・頭頸部外科   准教授

    2024.11

      More details

  • 新潟大学医学部   耳鼻咽喉科・頭頸部外科   講師

    2023.4 - 2023.10

      More details

  • 新潟大学医学部   耳鼻咽喉科・頭頸部外科   助教

    2022.4 - 2023.3

      More details

  • 新潟大学医歯学総合病院 耳鼻咽喉科・頭頚部外科   特任助教

    2019.1 - 2022.3

      More details

  • 癌研究会有明病院 頭頚科

    2009.4 - 2011.3

      More details

▶ display all

Research History

  • Niigata University   Sensory and Integrative Medicine, Biological Functions and Medical Control, Graduate School of Medical and Dental Sciences   Associate Professor

    2023.11

  • Niigata University   Institute of Medicine and Dentistry, Academic Assembly   Associate Professor

    2023.11

  • Niigata University   Otolaryngology, Head and Neck Surgery, University Medical and Dental Hospital   Lecturer

    2023.4 - 2023.10

  • Niigata University   Otolaryngology, Head and Neck Surgery, University Medical and Dental Hospital   Assistant Professor

    2022.4 - 2023.3

  • Niigata University   University Medical and Dental Hospital Otolaryngology, Head and Neck Surgery   Specially Appointed Assistant Professor

    2019.1 - 2022.3

 

Papers

  • 唾液腺導管癌におけるp53免疫組織化学染色の細胞質陽性パターンはTP53遺伝子変異を反映した予後不良因子となり得る 大規模多施設共同研究

    内海 由貴, 川北 大介, 山本 善也, 平井 秀明, 塚原 清彰, 加納 里志, 花澤 豊行, 大上 研二, 小澤 宏之, 山崎 恵介, 齊藤 祐毅, 植木 雄志, 中黒 匡人, 多田 雄一郎, 長尾 俊孝

    日本唾液腺学会誌   64   32 - 32   2024.12

     More details

    Language:Japanese   Publisher:日本唾液腺学会  

    researchmap

  • 唾液腺導管癌におけるp53免疫組織化学染色の細胞質陽性パターンはTP53遺伝子変異を反映した予後不良因子となり得る 大規模多施設共同研究

    内海 由貴, 川北 大介, 山本 善也, 平井 秀明, 塚原 清彰, 加納 里志, 花澤 豊行, 大上 研二, 小澤 宏之, 山崎 恵介, 齊藤 祐毅, 植木 雄志, 中黒 匡人, 多田 雄一郎, 長尾 俊孝

    日本唾液腺学会誌   64   32 - 32   2024.12

     More details

    Language:Japanese   Publisher:日本唾液腺学会  

    researchmap

  • PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumab. International journal

    Takashi Matsuki, Daisuke Kawakita, Hideaki Takahashi, Takuro Okada, Akihiro Sakai, Yushi Ueki, Hiroshi Tsuge, Kenji Hanyu, Kaho Momiyama, Ryusuke Shodo, Mayu Yamauchi, Yukiko Asako, Hideaki Hirai, Toshitaka Nagao, Yuichiro Tada

    Scientific reports   14 ( 1 )   19794 - 19794   2024.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Although immune checkpoint inhibitors (ICIs) are effective in some patients with salivary gland carcinoma (SGC), biomarkers which predict the efficacy and prognosis of SGC patients treated with pembrolizumab have not been identified. We conducted a multi-institutional retrospective cohort study to evaluate the efficacy and safety of pembrolizumab monotherapy in patients with recurrent and/or metastatic SGC and to determine optimal cut-off values of the combined positive score (CPS) and tumor proportion score (TPS) as numerical expression levels of programmed death-ligand 1 (PD-L1), which predict the efficacy of pembrolizumab. Furthermore, we investigated the association of patient characteristics and hematological markers with clinical outcomes, including overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). From 2016 to 2021, 27 patients were included in the analysis. ORR of SGC was 25.9%. Optimal cut-off values of CPS and TPS were 15 and 25%, respectively. ORRs of CPS-high and TPS-high were 55.6 and 75.0%, respectively, and significantly higher than those of CPS-low and TPS-low. Furthermore, patients with a low platelet-lymphocyte ratio (PLR) had a significantly longer PFS. No grade 4 or greater adverse events were observed. This study demonstrated the efficacy and safety of pembrolizumab monotherapy and identified optimal cut-off values of CPS and TPS.

    DOI: 10.1038/s41598-024-70779-8

    PubMed

    researchmap

  • The clinicopathological and prognostic significance of autonomic nerves in salivary duct carcinoma. International journal

    Manami Kajiwara, Hideaki Takahashi, Masato Nakaguro, Daisuke Kawakita, Hideaki Hirai, Yoshitaka Utsumi, Makoto Urano, Yukiko Sato, Kiyoaki Tsukahara, Satoshi Kano, Kenji Okami, Hiroyuki Ozawa, Keisuke Yamazaki, Takuro Okada, Akira Shimizu, Kenji Hanyu, Akihiro Sakai, Mayu Yamauchi, Mariko Sekimizu, Toyoyuki Hanazawa, Yuki Saito, Yushi Ueki, Yoshitaka Honma, Tomoyuki Arai, Sho Iwaki, Koji Yamamura, Yorihisa Imanishi, Yuichiro Sato, Yuichiro Tada, Toshitaka Nagao

    Virchows Archiv : an international journal of pathology   2024.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Many researchers have focused on the role of the autonomic nervous system in the tumor microenvironment. Autonomic nerves include the sympathetic and parasympathetic nerves, which are known to induce cancer growth and metastasis. However, in salivary duct carcinoma (SDC), a rare and highly malignant tumor, the issue should be investigated from both biological and therapeutic perspectives. We explored the clinicopathological and prognostic implications of the autonomic nerves in 129 SDCs. Immunohistochemistry was performed to determine the nature of each nerve using antibodies against S100, tyrosine hydroxylase (TH) as a sympathetic marker, and vesicular acetylcholine transporter (VAChT) as a parasympathetic marker. The area of each marker-positive nerve was digitized and evaluated quantitatively. Double immunofluorescence for TH and VAChT was performed in selected cases. The expression of the secreted neurotrophins was also examined. S100-positive nerves were present in the cancer tissue in 94 of 129 cases (72.9%). Among them, TH-positive sympathetic nerves and/or VAChT-positive parasympathetic nerves were identified in 92 cases (97.9%), and 59 cases (62.8%) had TH/VAChT-co-expressing nerves. Double immunofluorescence revealed a mosaic pattern of sympathetic and parasympathetic fibers in co-expressing nerve bundles. The presence of autonomic nerves, regardless of their area, was significantly associated with aggressive histological features, advanced T/N classification, and a poor prognosis, with shorter disease-free and overall survival. There was an association between some tumor immune microenvironment-related markers and the autonomic nerve status, but not the latter and the secreted neurotrophin expression. This study suggests that autonomic nerves might play a role in the progression of SDC.

    DOI: 10.1007/s00428-024-03873-x

    PubMed

    researchmap

  • 唾液腺導管癌におけるHER2低発現の臨床的意義

    加納 里志, 川北 大介, 花澤 豊行, 塚原 清彰, 岡田 拓朗, 大上 研二, 山崎 恵介, 齊藤 裕毅, 小澤 宏之, 植木 雄志, 本間 義崇, 中黒 匡人, 長尾 俊孝, 多田 雄一郎

    頭頸部癌   50 ( 2 )   137 - 137   2024.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    researchmap

▶ display all

MISC

  • 頭頸部化学放射線治療におけるエピシル口腔用液の予防的使用の有効性に関する前向き観察研究

    勝良剛詞, 山崎恵介, 吉田謙介, 曽我麻里恵, 田中雄介, 植木雄志, 正道隆介, 高橋剛史, 小林太一, 高村真貴, 林孝文

    頭頸部癌   48 ( 2 )   2022

  • 唾液腺導管癌における脂質関連蛋白発現の臨床病理学的意義

    平井 秀明, 多田 雄一郎, 中黒 匡人, 川北 大介, 佐藤 由紀子, 志村 智隆, 塚原 清彰, 加納 里志, 小澤 宏之, 大上 研二, 佐藤 雄一郎, 伏見 千宙, 清水 顕, 高瀬 総一郎, 岡田 拓朗, 佐藤 宏樹, 今西 順久, 大塚 邦憲, 渡部 佳弘, 酒井 昭博, 戎本 浩史, 富樫 孝文, 植木 雄志, 太田 久幸, 三枝 奈津季, 高橋 秀聡, 安藤 瑞生, 浦野 誠, 花澤 豊行, 長尾 俊孝

    日本唾液腺学会誌   60   24 - 25   2019.11

     More details

    Language:Japanese   Publisher:日本唾液腺学会  

    researchmap

  • 原発巣の特定に苦慮した甲状腺扁平上皮癌が疑われた一例

    今西 明, 安樂 匠, 三ツ間 友里恵, 矢口 雄大, 鈴木 達郎, 山田 貴穂, 曽根 博仁, 植木 雄志, 茂木 聡子, 梅津 哉, 大橋 瑠子, 佐々木 健太, 平田 哲大, 丸山 克也

    日本内分泌学会雑誌   95 ( 1 )   464 - 464   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本内分泌学会  

    researchmap

  • Multicenter phase i/II study of chemoradiotherapy with high-dose cddp for head and neck squamous cell carcinoma in Japan

    Hiroshi Matsuyama, Keisuke Yamazaki, Ryuichi Okabe, Yushi Ueki, Ryusuke Shodo, Jo Omata, Yuichiro Sato, Hisayuki Ota, Takeshi Takahashi, Masahiko Tomita, Yusuke Yokoyama, Takafumi Togashi, Hidefumi Aoyama, Eisuke Abe, Yasuo Saijo, Kouji Katsura, Marie Soga, Tadashi Sugita, Yasuo Matsumoto, Emiko Tsuchida, Ai'ata Horii

    Journal of Otolaryngology of Japan   122 ( 9 )   1269 - 1270   2019

     More details

    Language:Japanese   Publishing type:Rapid communication, short report, research note, etc. (scientific journal)   Publisher:Oto-Rhino-Laryngological Society of Japan Inc.  

    DOI: 10..3950/jibiinkoka.122.1269

    Scopus

    researchmap

  • 新潟大学医歯学総合病院における医科と歯科の連携の試み―アンケート結果報告―

    山崎恵介, 富樫孝文, 植木雄志, 岡部隆一, 松山洋, 船山昭典, 小田陽平, 新美奏恵, 三上俊彦, 金丸祥平, 勝見祐二, 勝良剛詞, 永田昌毅, 小林正治, 堀井新

    頭けい部癌   43 ( 2 )   255 - 255   2017.5

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

▶ display all

Presentations

  • 下咽頭癌化学放射線治療における嚥下リハビリテーションの有用性についての検討

    山崎 恵介, 森 香織, 正道 隆介, 富樫 孝文, 植木 雄志, 岡部 隆一, 松山 洋, 本田 耕平, 堀井 新

    頭頸部癌  2018.5 

     More details

    Language:Japanese  

    researchmap

  • 栄養サポートチーム(NST)介入による頭頸部癌化学放射線療法中の栄養状態についての前向き研究

    高橋 剛史, 佐藤 雄一郎, 太田 久幸, 若杉 亮, 植木 雄志, 正道 隆介

    頭頸部癌  2018.5 

     More details

    Language:Japanese  

    researchmap

  • 中・下咽頭表在癌における拡大内視鏡所見と深達度の検討

    岡部 隆一, 松山 洋, 正道 隆介, 富樫 孝文, 植木 雄志, 山崎 恵介, 本田 耕平, 堀井 新

    頭頸部癌  2018.5 

     More details

    Language:Japanese  

    researchmap

  • 頭頸部癌に対するNivolumab投与報告

    松山 洋, 本田 耕平, 山崎 恵介, 岡部 隆一, 植木 雄志, 富樫 孝文, 正道 隆介, 堀井 新

    頭頸部癌  2018.5 

     More details

    Language:Japanese  

    researchmap

  • 当科における再発頭頸部扁平上皮癌のCetuximab併用1次治療不応に対する2次治療の有効性と安全性の検討

    富樫 孝文, 正道 隆介, 植木 雄志, 岡部 隆一, 山崎 恵介, 本田 耕介, 松山 洋, 堀井 新

    頭頸部癌  2018.5 

     More details

    Language:Japanese  

    researchmap

▶ display all

Research Projects

  • Development of novel head and neck cancer therapy focusing PLOD2 suppression driven by cyclin-dependent kinase inhibition.

    Grant number:22K16896

    2022.4 - 2025.3

    System name:Grants-in-Aid for Scientific Research Grant-in-Aid for Early-Career Scientists

    Research category:Grant-in-Aid for Early-Career Scientists

    Awarding organization:Japan Society for the Promotion of Science

      More details

    Grant amount:\4420000 ( Direct Cost: \3400000 、 Indirect Cost:\1020000 )

    researchmap

  • Study on the process of carcinogenesis by HPV infection comparing pharynx and cervix

    Grant number:22K10506

    2022.4 - 2025.3

    System name:Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C)

    Research category:Grant-in-Aid for Scientific Research (C)

    Awarding organization:Japan Society for the Promotion of Science

      More details

    Grant amount:\4160000 ( Direct Cost: \3200000 、 Indirect Cost:\960000 )

    researchmap